Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
|
30833304 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We present an electrolyte-gated graphene field effect transistor (GFET) nanosensor using aptamer for rapid, highly sensitive and specific detection of a lung cancer biomarker interleukin-6 (IL-6) with enhanced stability.
|
31273548 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our results elucidated a crucial role of LDOC1 in lung cancer and revealed how LDOC1 acts as a bridge between tobacco exposure and the IL-6/JAK2/STAT3 loop in this human malignancy.
|
30634502 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Body and muscle weight, grip strength, physical activity, muscle morphometry, apoptotic nuclei, troponin-I systemic levels, interleukin-6, proteolytic markers, and tyrosine release, and apoptosis markers were determined in diaphragm and gastrocnemius muscles of lung cancer (LP07 adenocarcinoma cells) mice (BALB/c) treated with monoclonal antibodies (mAbs), against immune check-points and pathways (CD-137, cytotoxic T-lymphocyte associated protein-4, programed cell death-1, and CD-19; N = 10/group).
|
30851071 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The poor prognosis of LC complicated with TE disease has positive correlations with PT, FIB, D-D, IL-6 and PCT, and a negative association with APTT, providing a certain reference as a prognostic value in the diagnosis and treatment.
|
31128010 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, this occurred even when the pathway was overstimulated with its ligand interleukin 6 (IL-6), which is frequently overexpressed in lung cancer patients who show poor clinical outcomes.
|
31412593 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic IL-6 inflammation, as quantified by repeated measures was associated with incident lung cancer in Model 1, but not Model 2.
|
30078713 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lung cancer patients exhibited significantly elevated serum IGFBP-1, TNF RI, VEGF, TNF RII, PAI-1 and IL-6 levels compared to controls (P<0.05) and most of these adipocytokines revealed a modest discriminative ability for the diagnosis of lung cancer, while BDNF were lower in patients (P<0.05).
|
31559061 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sulforaphane Inhibits the Acquisition of Tobacco Smoke-Induced Lung Cancer Stem Cell-Like Properties <i>via</i> the IL-6/ΔNp63α/Notch Axis.
|
31367260 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in IL-6, IL6-R, and IL6-ST genes were assessed in 120 controls and 120 patients with confirmed lung cancer diagnosis.
|
31468132 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the role of miR-206 in IL6-induced gefitinib-resistant EGFR-mutated lung cancer cell lines.
|
31507089 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, ATM modulates vimentin expression to facilitate IL-6-induced epithelial-mesenchymal transition and metastasis in lung cancer, indicating that ATM and vimentin might be potential therapeutic targets for inflammation-associated lung cancer metastasis.
|
31100307 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of Tyrosine-Phosphorylated STAT3 in Human Breast and Lung Cancer Cells by Manuka Honey is Mediated by Selective Antagonism of the IL-6 Receptor.
|
31491838 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified and validated 10 proteins associated with lung cancer in AAS, some that were common between EAs and AAs (C-reactive proteins [OR: 2.90; 95% confidence interval (CI): 1.99-4.22], interferon γ [OR: 1.55; 95% CI: 1.10-2.19], interleukin 6 [OR: 6.28; 95% CI: 4.10-9.63], interleukin 8 [OR: 2.76; 95% CI: 1.92-3.98]) and some that are only observed among AAs (interleukin 10 [OR: 1.69; 95% CI: 1.20-2.38], interleukin 15 [OR: 2.83; 95% CI: 1.96-4.07], interferon gamma-induced protein 10 [OR: 1.54; 95% CI: 1.09-2.18], monocyte chemotactic protein-4 [OR: 0.54; 95% CI: 0.38-0.76], macrophage inflammatory protein-1 alpha [OR: 1.57; 95% CI: 1.12-2.21], and tumor necrosis factor β [OR: 0.52; 95% CI: 0.37-0.74]).
|
30953795 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus using the well-characterized model human lung cancer model cell line (BEAS-2B), poly I:C RNA, LL37 peptide, or LL37-poly I:C complexes were loaded onto ZnO NP and delivered to BEAS-2B lung cells, and the effect on the main cancer regulating cytokine, IL-6 determined by ELISA.
|
31771091 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combination of EGFR-TKI and anti-IL-6 antibody moderately improved the sensitivity of EGFR-TKI in lung cancer cell with EGFR mutation.
|
29101033 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This in-depth study not only helped to elucidate the mechanism of how IL-6 promotes lung cancer but also provided new ideas and entry points to resolve the low specificity and sensitivity of lung cancer-related tumour markers.
|
29869537 |
2018 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.
|
29134640 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between lung cancer incidence and survival and 23 polymorphisms descriptive of 11 inflammation-related genes (interferon gamma gene [IFNG], interleukin 10 gene [IL10], interleukin 1 alpha gene [IL1A], interleukin 1 beta gene [IL1B], interleukin 2 gene [IL2], interleukin 4 receptor gene [IL4R], interleukin 4 gene [IL4], interleukin 6 gene [IL6], prostaglandin-endoperoxide synthase 2 gene [PTGS2] (also known as COX2), transforming growth factor beta 1 gene [TGFB1], and tumor necrosis factor alpha gene [TNFA]) was evaluated.
|
29408308 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that the interleukin (IL)-6/ IL-6 receptor (IL-6R) signaling pathway contributes to the pathogenesis of lung cancer.
|
30127882 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The signaling pathways of interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) play an important role in the progression of lung cancer, and this study aimed to explore whether they can synergistically promote the progression of non-small cell lung cancer (NSCLC).
|
30604632 |
2018 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of ERβ/IL6 in 289 lung cancer samples was assessed by immunohistochemistry.
|
29970138 |
2018 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
USP24 stabilizes p300 and β-TrCP to increase the levels of histone-3 acetylation and NF-κB, and decreases the levels of DNMT1 and IκB, thereby increasing IL-6 transcription in M2 macrophages and lung cancer cells, results in cancer malignancy finally.
|
30266897 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We observed a higher lung cancer risk for participants with elevated concentrations of IL-6 and IL-8.
|
27998891 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We replicated the previous observations that IL-6 is associated with prognosis of lung cancer and extended its utility to prognosis in this highly-selected population of stage I lung adenocarcinoma patients.
|
28402963 |
2017 |